SOLICITATION NOTICE
66 -- Reagents for Genetic Analysis
- Notice Date
- 8/6/2014
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- HHS-NIH-NHLBI-CSB-HI-2014-215-CDB
- Archive Date
- 8/28/2014
- Point of Contact
- Chris Bocus, Phone: 3014027888
- E-Mail Address
-
chris.bocus@nih.gov
(chris.bocus@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Introduction: THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisitions (OA), intends to negotiate and award a purchase order on a sole source noncompetitive basis to provide reagents for genetic analysis (i.e. sequencing) to Life Technologies Corporation, 3175 Staley Road, Grand Island, NY, 14072-2090. Background: The mission of the NHLBI Division of Intramural Research (DIR) is to perform robust scientific and clinical research leading to a better understanding of biology and clinical pathology. To attain this goal, we have built a strong basic science foundation and coupled it closely with innovative technology development and outstanding clinical research both at the NIH Clinical Center and in partnership with local hospitals. The purview of our research is broad, encompassing investigations into the basic principles of molecular, cellular, and organ-level biology and their relationship to disease. Some current areas of fundamental interest include single molecule structure; protein assembly; molecular and cell biology; cell signaling and motility; membrane trafficking; physiology; systems biology; engineering and technology development. Insights into disease mechanisms derived from basic studies form the basis for translational research into new diagnostic and therapeutic approaches. DIR investigators also conduct concept-based clinical studies in the areas of interventional and surgical cardiology; pulmonary medicine; sickle cell anemia; bone marrow transplant; and hematologic disorders. Providing state-of-the-art training in basic, translational, and clinical research for the next generation of scientific and clinical leaders is a high priority. This program provides opportunities for scientists and trainees to work together towards a better understanding of molecular machines, the cell, the body, and ultimately the treatment of human diseases. The Hematology Branch (the lab) conducts research on the genetic basis of bone marrow failure diseases, viruses, acute leukemias, and hepatic cirrhosis. Some of the basic approach to these studies is the performance of genetic sequencing, for example, the multiple genes involved in telomere erosion and repair in blood samples of thousands of patients with acquired aplastic anemia and other syndromes per year or obtaining sequences of new viruses. The genetic analyzers have specific reagents/consumables associated with it. The Hematology Branch perform Clinical Laboratory Improvement Amendment (CLIA) certified testing for TERT/TERC sequence mutations. These clinical test are required as described in specific clinical protocols establish through NHLBI. Purpose and Objective: The objective of this procurement is to provide reagents/consumables for genetic analysis. The Hematology Branch genetic analysis projects require reagents specific to the genetic analyzing machine. The Hematology Branch owns three Applied Biosystems/Life Technologies Inc. ABI 3130xl Genetic Analyzers. The only available reagents to perform genetic analysis on this machine are manufactured solely by ABI and are proprietary. The reagents from ABI will serve to perform genetic analysis. The results of the testing provide critical information about the of the patients's genes, rearrangements of chromosomes, or mutations. This data will aid in the subsequent treatment of patients as detailed in the clinical protocols. The vendor/contractor will supply the reagents requested and the investigators in the laboratory will use the reagents for research purposes or clinical testing. The government expects the reagents to be delivered in a timely manner and in good condition. Contractor Requirements: 1. The vendor will send the reagents/consumables as agreed upon in the contract. 2. The vendor will shipped the reagents/consumables in proper temperature conditions 3. The shipment of reagents/consumables should arrive at the times agreed upon. 4. Vendor should make sure that the correct reagents/consumables and the correct quantities are shipped. 5. Reagents/consumables delivered should not be within 3 months of expiration date. 6. The quantity of reagents/consumables is delivered quarterly for a period of one year. Government Responsibilities: The government will receive the reagents/consumables and check for errors. If there are errors in the shipment, the government will notify the vendor immediately. Reporting Requirements and Deliverables: Once the reagents/consumables are delivered & inspected, the packaging slip will be signed and turned over to the purchasing agent. Invoicing by the vendor should be made once they have made delivery satisfactorily. If there are problems with the purchase, the purchasing agent will resolve it. Program Management and Control Requirements: The reagents/consumables will be managed by the Hematology Branch staff and distributed to investigators who need them. Inspection and Acceptance Requirements: The reagents/consumables will be inspected by receiving Hematology Branch staff at NIH, 10 Center Dr., Bethesda, MD 20892. Hematology Branch staff will inspect the reagents/consumables delivered and accept them if the reagents/consumables are in accordance with terms and contract. If problems exist with the reagents/consumables, Hematology Branch staff will contact the vendor and reject the shipment and arrange for a replacement as necessary. The reagents/consumables will be inspected for accuracy, damage or expiration. Anticipated Period of Performance: Negotiated Upon Award. Justification: The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted as prescribed in FAR Part 10-Market Research. 1. Life Technologies is the sole provider of the BDT reagents, the only available reagents to perform genetic analysis for the lab's genetic analyzers. Regulatory Authority: This acquisition is conducted under the authority of 41 U.S.C. 253(c) as set forth in FAR Part 13.106-1 (b) (1), Soliciting from a single source not exceeding the simplified acquisition threshold, and is exempt from the requirements of FAR Part 6, Competition Requirements. Additional Information: Industry Classification (NAICS) Code is 325414, Biological Product (except Diagnostic) Manufacturing and the Small Business Size Standard is 500 Employees. This acquisition is conducted under the procedures as prescribed in FAR subpart 12-Acquisition of Commercial Items and FAR subpart 13-Simplified Acquisition Procedures. The solicitation document, the incorporated provisions and clauses are those in the Federal Acquisition Circular 2005-76, effective July 25, 2014. The determination by the Government to award a purchase order on a sole source noncompetitive to provide reagents for genetic analysis (i.e. sequencing) to Life Technologies Corporation, 3175 Staley Road, Grand Island, NY, 14072-2090, is based upon the market research conducted in accordance with one or more of the techniques specified in FAR Part 10-Market Research, Subpart 10.002(b)(2). This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by August 13, 2014 at 12:00 p.m. EST. Responses must reference synopsis number HHS-NIH-NHLBI-CSB-HI-2014-215-CDB, may be submitted to the National, Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6121A, Bethesda, Maryland 20892-7902, Attention: Chris Bocus. Response may be submitted electronically to chris.bocus@ nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/HHS-NIH-NHLBI-CSB-HI-2014-215-CDB/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03454225-W 20140808/140807022949-90de24c323adeecd0c2fe55a1fbb89f3 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |